| Bioactivity | Mipomersen (sodium) is a second-generation 20-base phosphorothioate ASO targeted to human apoB-100[1][2]. |
| Invitro | Mipomersen predominantly distributes to the liver and decreases the production of apoB-100, the primary structural protein of the atherogenic lipoproteins including low density lipoprotein (LDL), thereby reducing plasma LDL-cholesterol and apoB-100 concentrations[2].Apolipoprotein (apo) B, a large amphipathic protein, plays a fundamental role in human lipoprotein metabolism. ApoB-100 is also a ligand for LDL receptor-mediated endocytosis of LDL by cells[2]. |
| Name | Mipomersen sodium |
| CAS | 629167-92-6 |
| Molar Mass | 7595.00 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture) |
| Reference | [1]. Philip Hair, et al. Mipomersen sodium: first global approval. Drugs. 2013 Apr;73(5):487-93. [2]. Damon A Bell, et al. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs. 2011 Feb;20(2):265-72. |